Adenosine regulates the IL-1 beta-induced cellular functions of human gingival fibroblasts.
In this study we examined the influence of adenosine on the cellular functions of human gingival fibroblasts (HGF), such as the production of inflammatory cytokines and extracellular matrices (ECM), and the expression and function of adhesion molecules. Concerning the expression of adenosine receptors, RT-PCR analysis revealed that HGF expressed adenosine receptor A1, A2a and A2b, but not A3 mRNA. Ligation of adenosine receptors by adenosine or its related analogue, 2-chloroadenosine (2-CADO), N(6)-cyclopentyladenosine (CPA) or CGS21680 synergistically increased IL-1beta-induced IL-6 and IL-8 production. In terms of ECM expression, adenosine and the adenosine receptor agonists, 2-CADO and CPA, enhanced constitutive and IL-1beta-induced expression of hyaluronate synthase mRNA, but not the mRNA levels of other ECM, such as collagen type I, III and fibronectin. Moreover, the adherence of IL-1beta-stimulated HGF to activated lymphocytes was also inhibited by adenosine, which is in part explained by the fact that adenosine down-regulated the IL-1beta-induced expression of ICAM-1 on HGF. These results provide new evidence for the possible involvement of adenosine in the regulation of inflammatory responses in periodontal tissues.
Murakami
S
S
Department of Periodontology, Division of Oral Biology and Disease Control, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan.
Hashikawa
T
T
Saho
T
T
Takedachi
M
M
Nozaki
T
T
Shimabukuro
Y
Y
Okada
H
H
D015762:2-Chloroadenosine / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology / Q000502:physiology*; D000276:Adjuvants, Immunologic / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D024042:Collagen Type I / Q000235:genetics; D024061:Collagen Type III / Q000235:genetics; D015536:Down-Regulation / Q000276:immunology; D004357:Drug Synergism; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D005353:Fibronectins / Q000235:genetics; D005881:Gingiva / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000096:biosynthesis / Q000235:genetics; D016695:Glycosyltransferases; D006801:Humans; D000076002:Hyaluronan Synthases; D007111:Immunity, Cellular / Q000187:drug effects / Q000235:genetics; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D016209:Interleukin-8 / Q000096:biosynthesis / Q000235:genetics; D007797:Laminin / Q000235:genetics; D008565:Membrane Proteins; D058906:Purinergic P1 Receptor Agonists; D012333:RNA, Messenger / Q000096:biosynthesis; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1 / Q000096:biosynthesis / Q000235:genetics; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D014166:Transferases; D029867:Xenopus Proteins
D000276:Adjuvants, Immunologic; D024042:Collagen Type I; D024061:Collagen Type III; D005353:Fibronectins; D007375:Interleukin-1; D015850:Interleukin-6; D016209:Interleukin-8; D007797:Laminin; D008565:Membrane Proteins; D058906:Purinergic P1 Receptor Agonists; D012333:RNA, Messenger; D043684:Receptor, Adenosine A3; D018047:Receptors, Purinergic P1; D029867:Xenopus Proteins; D018799:Intercellular Adhesion Molecule-1; D015762:2-Chloroadenosine; D014166:Transferases; D016695:Glycosyltransferases; D014453:Glucuronosyltransferase; C056944:HAS1 protein, Xenopus; D000076002:Hyaluronan Synthases; D000241:Adenosine